228
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx® in multiple myeloma

, , , , &
Pages 1478-1481 | Received 27 Mar 2017, Accepted 10 Sep 2017, Published online: 10 Oct 2017
 

Acknowledgements

Funding for the study and for editorial assistance with this manuscript was provided by Sun Pharmaceutical Industries Ltd. Medical writing support was provided by Claire Aukim-Hastie and Diane Kwiatkoski of QuintilesIMS.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1382692.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.